A total of SEK 14 million is invested in the company by Kempestiftelserna along with the company’s largest shareholder, Nascent Invest.

Kempestiftelserna is two foundations committed to supporting groundbreaking research and initiatives in Västerbotten, Norrbotten, and Västernorrland. For example, in 2023, Kempestiftelserna along with Umeå University and Knut och Alice Wallenbergs Stiftelse, invested SEK 67,5 million in the Laboratory for Molecular Infection Medicine Sweden (MIMS) at Umeå University.

This partnership reflects our commitment to fostering advancements in medical research at and around Umeå University and thereby improving public health.

“We believe in the innovative approach of QureTech Bio and are proud to support the company’s efforts in fighting antimicrobial resistance (AMR). This partnership reflects our commitment to fostering advancements in medical research at and around Umeå University and thereby improving public health,” says Alice Kempe, Chairman of the board at Kempestiftelserna.

Accelerate development programs

QureTech Bio is developing new solutions to combat disease-causing bacteria to tackle AMR and the the CEO of QureTech Bio, Markus Thor explains that this financial support will specifically aid in targeting infectious bacteria resistant to conventional antibiotics.

”This investment will enable us to accelerate our development programs. Focusing on a completely new class of antibiotics, the company is set to make significant strides in addressing antimicrobial resistance,” he says.